Institutional profile: Program in pharmacogenomics at the ohio state university medical Center

Pharmacogenomics

Volumn 13, Issue 7, 2012, Pages 751-756

  Kitzmiller, Joseph P ^a   Embi, Peter J ^a   Manickam, Kandamurugu ^a   Sweet, Kevin M ^a   Phelps, Mitch A ^a   Jackson, Rebecca D ^a   Marsh, Clay B ^a   Sadee, Wolfgang ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATORVASTATIN; CLOPIDOGREL; CYCLOSPORIN; CYTOCHROME P450 3A4; MEVINOLIN; SAQUINAVIR; SEROTONIN 2A RECEPTOR; SIMVASTATIN; TACROLIMUS; VERAPAMIL;

BIOINFORMATICS; CLINICAL RESEARCH; GENE FREQUENCY; HEALTH CARE; HEALTH CENTER; HEALTH PROGRAM; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERLIPIDEMIA; LABORATORY; MOLECULAR GENETICS; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENOMICS; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; UNITED STATES; EDUCATION; MEDICAL EDUCATION; NOTE; PHARMACOGENETICS; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; EDUCATION, MEDICAL; HUMANS; OHIO; PHARMACOGENETICS;

EID: 84861170448     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.46     Document Type: Review

References (11)

1. Hudson KL. Genomics, health care, and society. N. Engl. J. Med. 365(11), 1033-1041 (2011).
2. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11(4), 274-286 (2011).
3. Elens L, van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on a calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12(10), 1383-1396 (2011).
4. Elens L, Bouamar R, Hesselink DA et al. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet. Genomics doi:10.1097/FPC.0b013e328351f3c1 (2012) (Epub ahead of print).
5. Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574-1583 (2011).
6. Zuk O. The mystery of missing heritability: genetic interactions create phantom heritability. Proc. Natl Acad. Sci. USA 109(4), 1193-1198 (2012).
7. Payne PR, Embi PJ, Sen CK. Translational informatics: enabling high-throughput research paradigms. Physiol. Genomics 39(3), 131-140 (2009).
8. Embi PJ, Payne PR. Clinical research informatics: challenges, opportunities and definition for an emerging domain. J. Am. Med. Inform. Assoc. 16(3), 316-327 (2009).
9. Payne PR, Embi PJ, Niland J. Foundational biomedical informatics research in the clinical and translational science era: a call to action. J. Am. Med. Inform. Assoc. 17(6), 615-616 (2010).
10. Sequist LV, Heist RS, Shaw AT et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann. Oncol. 22(12), 2616-2624 (2011).
11. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice. Cleve. Clin. J. Med. 78(4), 243-257 (2011).